Quantcast

Buspirone for the treatment of anxiety-related symptoms in Angelman syndrome: a case series.

Research paper by Kayla K Balaj, Lisa L Nowinski, Brianna B Walsh, Jennifer J Mullett, Michelle L ML Palumbo, Ronald L RL Thibert, Christopher J CJ McDougle, Christopher J CJ Keary

Indexed on: 27 Jan '19Published on: 27 Jan '19Published in: Psychiatric genetics



Abstract

Angelman syndrome (AS) is a neurogenetic disorder associated with impaired expression of the ubiquitin-protein ligase E3A gene on chromosome 15. AS results in intellectual disability with limited expressive language, epilepsy, ataxia, sleep impairment, and problematic behavior which may include anxiety. Buspirone is a serotonin (5-HT)1A receptor partial agonist used in the treatment of anxiety disorders and may, therefore, have a treatment role for patients with AS. We describe three patients who were given open-label buspirone for the treatment of behaviors thought to be related to anxiety. We found significant improvement in symptoms of anxiety with buspirone. Patients tolerated long-term usage of the medication. The findings of this study suggest that buspirone may be effective for the amelioration of behaviors related to anxiety in patients with AS, and well tolerated. Limitations include the open-label nature of these treatments, the small sample size and the absence of a control group.